Serum Preptin and Amylin Levels in Polycystic Ovary Syndrome Patients
1 other identifier
observational
80
1 country
1
Brief Summary
Preptin and amylin are pancreatic hormones which participate in glucose homeostasis. This study aims to evaluate how serum preptin and amylin levels are altered in polycystic ovary syndrome (PCOS) patients and healthy women based on BMI groups .
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2017
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 28, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 7, 2017
CompletedFirst Submitted
Initial submission to the registry
June 12, 2018
CompletedFirst Posted
Study publicly available on registry
July 16, 2018
CompletedJuly 16, 2018
July 1, 2018
5 months
June 12, 2018
July 13, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Serum Preptin and Amylin Levels with Respect to Body Mass Index in Polycystic Ovary Syndrome Patients
Serum Preptin and Amylin Levels will compare between groups
six months
Study Arms (2)
Polycyctic ovary sendrome (PCOS)
these women who have PCOS, we will use their blood samples
Healty groups
These women who have reguler menstrual cycle, no akne or hirsutism, we will use their boold samples
Interventions
we will take both of group blood samples to compare them serum preptin and amylin
Eligibility Criteria
Polycystic ovary syndrome
You may qualify if:
- the patients with PCOS
You may not qualify if:
- Cushing's syndrome 21-hydroxylase deficiency Congenital adrenal hyperplasia Thyroid dysfunction Hyperprolactinemia Diabetes Chronic cardiovascular Hepatic, renal, and hematologic diseases Malignancies Using oral contraceptives, anti-androgens, glucocorticoids, anti-hypertensives, anti-diabetics, calcium supplements and anti-obesity drugs and those who smoke or consume alcohol
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Recep Tayyip Erdogan University
Rize, 53000, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Senol sentürk, PhD
Recep Tayyip Erdogan University
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Serum Preptin and Amylin Levels in Polycystic Ovary Syndrome Patients
Study Record Dates
First Submitted
June 12, 2018
First Posted
July 16, 2018
Study Start
June 28, 2017
Primary Completion
November 30, 2017
Study Completion
December 7, 2017
Last Updated
July 16, 2018
Record last verified: 2018-07